Citius Pharma Q1 2025 net loss $10.3M; prepares LYMPHIR launch H1 2025

Citius Pharmaceuticals, Inc.

2025-Q1 EPS reported -$1.30 vs consensus -$0.39 ▼ miss (-232.5%)

Net loss of $10.3M ($1.30 per share) vs. $9.2M ($1.45) in Q1 2024; cash $1.1M as of Dec 31, 2024.
G&A expenses rose to $5.4M on pre-launch LYMPHIR activities; R&D fell to $2.1M as trials completed.
LYMPHIR received permanent J-code (J9161) effective April 1, 2025; launch expected in first half 2025.
Citius Oncology engaged Jefferies to evaluate strategic alternatives; raised $6.5M in equity placements.
Nasdaq compliance regained after 1-for-25 reverse stock split in November 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.